期刊文献+

卡马西平诱导大鼠骨髓抑制模型的建立 被引量:3

Establishment of rat bone marrow inhibition model induced by carbamazepine
下载PDF
导出
摘要 目的:建立卡马西平(CBZ)诱导的骨髓抑制大鼠模型。方法:SD大鼠72只,随机分为正常对照组和模型组。正常对照组12只,每d灌胃蒸馏水,其余不做任何处理。模型组60只,以CBZ灌胃,剂量由600mg/kg始,每5d增加200mg/kg,至1200mg/kg维持,共计灌胃120d,然后停用CBZ,继续观察30d。于给药第30d、60d、90d、120d及停药30d后各取大鼠12只处死,观察外周血象、骨髓象的变化。结果:模型组大鼠一般情况差,给药60d后大鼠即开始表现全血抑制,其中红系造血母细胞的抑制更为明显。在CBZ撤除30d内,造血系统功能未见明显恢复。结论:成功建立了CBZ诱导的骨髓抑制大鼠模型。 Aim : To establish the model of rat bone marrow inhibition induced by carbamazepine tablets ( CBZ). Methods: A total of 72 rats were randomly allocated into 2 groups. The model group( n = 60) was given CBZ by gavage from a dose of 600 mg/kg and increased by 200 mg/kg every 5 d till increased to 1 200 mg/kg and mainained the dose till the end of administration. The normal control group( n = 12) was given distilled water. On the 30th d,60th d,90th d, 120th d,and 150th d,12 rats in model group and rats in normal control group on the 150th d were executed. The changes of peripheral hemogram and bone marrow matrix were observed. Results :The general condition of model group was bad and from the 60th d,the rats presented the whole blood inhibition, and the inhibition of hemocytoblast was more obvious. Within 30 d after the withdrawl of CBZ, the bone marrow function had no obvious recovery. Conclusion : The rat bone marrow inhibition model induced by CBZ is successfully established.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2005年第6期1002-1004,共3页 Journal of Zhengzhou University(Medical Sciences)
基金 河南省科技攻关基金资助项目991170620 河南省教育科研基金资助项目1999360018
关键词 卡马西平 骨髓抑制 不良反应 大鼠 动物模型 carbamazepine inhibition of bone marrow adverse effect rat animal model
  • 相关文献

参考文献4

二级参考文献29

  • 1王艺,孙道开.小儿抗癫痫药物的不良反应[J].中国实用儿科杂志,2000,15(9):570-574. 被引量:20
  • 2张强,孙道开.卡马西平致药源性皮肤及肝脏损害2例报告[J].中国实用儿科杂志,1997,12(2):124-124. 被引量:6
  • 3Bryant AE 3rd, Dreifuss FE. Valproic acid hepatic fatalities.Ⅲ. U. S experience since 1986. Neurology,1996,46(2) :465.
  • 4Pellock JM.Felbamate in epilepsy therapy: evaluating the risks.Drug Saf,1999,21:225-239.
  • 5Mackay FJ,Wilton LV,Pearce GL,et al.Safety of long-term lamotrigine inepilepsy.Epilepsia,1997,38: 881-886.
  • 6Jones MW.Topiramate--safety and tolerability.Can J Neurol Sci,1998,25: S13-S15.
  • 7Conley EL,Coley KC,Pollock BG,et al.Prevalence and risk of thrombocytopenia withvalproic acid: experience at a psychiatric teaching hospital.Pharmacotherapy,2001,21:1325-1330.
  • 8Trannel TJ,Ahmed I,Goebert D.Occurrence of thrombocytopenia in psychiatricpatients taking valproate.Am J Psychiatry,2001,158: 128-130.
  • 9Ko CH,Kong CK,Tse PW.Valproic acid and thrombocytopenia: cross-sectionalstudy.Hong Kong Med J,2001,7: 15-21.
  • 10Verrotti A,Greco R,Matera V,et al.Platelet count and function in childrenreceiving sodium valproate.Pediatr Neurol,1999,21: 611-614.

共引文献42

同被引文献59

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部